This report shares the results of a value proposition study that PATH conducted to better understand stakeholder perspectives in four countries on potential use cases and target populations for a human hookworm vaccine and to explore the idea of a hookworm/malaria combination vaccine. The Democratic Republic of Congo, Ghana, Malawi, and Uganda were selected for the study because they all have demonstrated hookworm and malaria disease burdens. Providing protection against both diseases with a single vaccine could offer an efficient, effective, and affordable way to improve health in low- and middle-income countries.